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Abstract Physiologically increased pancreatic uptake at the
head/uncinate process is observed in more than one-third of
patients after injection of one of the three 68Ga-labelled
octreotide-based peptides used for somatostatin (sst) receptor
(r) imaging. There are minor differences between these 68Ga-
sstr-binding peptides in the imaging setting. On 68Ga-sstr-im-
aging the physiological uptake can be diffuse or focal and
usually remains stable over time. Differences in the maximal
standardised uptake values (SUVmax) reported for the normal
pancreas as well as for pancreatic neuroendocrine tumour
(PNET) lesions may be related to several factors, including
(a) differences in the peptide binding affinities as well as dif-
ferences in sstr subtype expression of pancreatic α- and β-
cells, and heterogeneity / density of tumour cells, (b) differ-
ences in scanner resolution, image reconstruction techniques
and acquisition protocols, (c) mostly retrospective study de-
signs, (d) mixed patient populations, or (e) interference with
medications such as treatment with long-acting sst analogues.
The major limitation in most of the studies lies in the lack of
histopathological confirmation of abnormal findings. There is
a significant overlap between the calculated SUVmax-values
for physiological pancreas and PNET-lesions of the head/
uncinate process that do not favour the use of quantitative
parameters in the clinical setting. Anecdotal long-term fol-
low-up studies have even indicated that increased uptake in
the head/uncinate process still can turn out to be malignant
over years of follow up. SUVmax-data for the pancreatic body
and tail are limited. Therefore, any visible focal tracer uptake
in the pancreas must be considered as suspicious for malig-
nancy irrespective of quantitative parameters. In general, sstr-
PET/CT has significant implications for the management of
NET patients leading to a change in treatment decision in
about one-third of patients. Therefore, follow-up with 68Ga-
sstr-PET/CT is mandatory in the clinical setting if uptake in
the head/uncinate process is observed.
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Pancreas anatomy (Fig. 1) and surgery options
(Fig. 2)
Removal of the primary tumour significantly prolongs
survival of pancreatic neuroendocrine tumour (PNET)
patients for both those with distant metastases and those
without metastases. Therefore, early diagnosis/detection
of PNETs is crucial for patient management. In general,
surgery for PNETs is faced by two characteristic facts.
On the one hand, preoperative diagnosis/localisation is
challenging, and on the other hand, surgery of the pan-
creas can result in life-threatening complications. Once
the diagnosis is established, choice for the optimal sur-
gical procedure has to be made [1]. The criteria that
influence this decision are the localisation of the
PNET within the pancreas (caput, corpus, tail), type of
PNET (i.e., insulinoma, gastrinoma, non-functioning tu-
mours, multiple PNETs in multiple endocrine neoplasia
(MEN) I syndrome), and localisation of the PNET in
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correlation to the pancreatic duct. Preservation of endo-
crine function, if at all possible, should be one consid-
eration in the choice of operation. A radical resection
should always be considered, at least for tumours of
>2 cm even in cases of known distant metastases with
impact on further prognosis [2]. A total of more than
60 % 5-year survival rates can be achieved after R 0-
resection, independently of the extent of surgery with
surgical mortality below 5 % and acceptable morbidity
between 20 and 30 % in specialised centres [3]. For
preoperative localisation of small PNET/duodenal wall
68Ga-somatostatin(sst)-receptor(r)-PET/CT showed high
sensitivity for delineation of malignant lesions [4].
Pancreas imaging modalities
There are different metabolic imaging methods, various tracers,
and several anatomic modalities to stage PNETs. In principle,
morphologic techniques bear the risk of underestimation. 68Ga-
sstr-PET/CT in combination with diffusion-weighted magnetic
resonance imaging (DW-MRI) is currently the most promising
technique for investigatingNETs. The calculated sensitivity from
pooled data of 52 studies was highest for sstr-PET compared to
endoscopic or intraoperative ultrasound, sstr-scintigraphy, dual-
phase (DP)-CT, DW-MRI, and 18F-FDG-PET, according to a
recent extensive review by Bodei et al [5]. In a small number
of patients, other molecular PET tracers such as 18F-DOPA, 11C-
Fig. 1 Normal pancreatic
anatomy. Image obtained from a
cadaveric pancreatic specimen.
Courtesy of Marko Konschake,
M.D., Anatomical Institute,
Medical University of Innsbruck,
Austria
Fig. 2 Thompson procedure.
Operative specimens of multiple
endocrine neoplasia (MEN) I-
associated Zollinger–Ellison syn-
drome with hypergastrinemic-
induced Type II NET of the
stomach (Thompson procedure).
(1) Specimen of left pancreatec-
tomy with multiple small PNETs.
(2) Metastasis of omentum majus
not detected preoperatively. (3)
Locally excised Type II NET of
stomach induced by duodenal
gastrinomas (5,6). (4) Enucleated
non functioning PNET of pancre-
atic head. (5,6) Submucosal
gastrinomas of duodenum excised
by duodenotomy after
transillumination
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5-HTP [6] or the 68Ga-exendin-4 targeting glucagon-like pep-
tide-1 (GLP-1) [7] receptor tracer may locate a lesion when sstr-
PET/CT is negative.
Basis of pancreatic imaging with sstr-ligands
Expression of sstr subtypes on normal pancreatic
and on pancreatic neuroendocrine tumour cells
For PNETs peptide receptor imaging has been a challenge
over the last 20 years, and still is. In principal, NET cells
may express much higher amounts of sstr than normal tissue
or blood cells providing the basis for imaging and treatment of
sstr-positive tumour lesions. However, different primary tu-
mours and metastases may express different amounts as well
as different types of sstr-subtypes, and peptide ligands may
bind differently to the five sstr-subtypes known [8, 9].
In fact, not too much is known about the normal in-vivo
expression of sstr—and there may be large inter-individual
variation as well. Physiologically, several normal organs show
an increased sstr-expression. Therefore, different organs in-
cluding the spleen, liver, pituitary, thyroid, kidneys, adrenal
glands, salivary glands, and Bthe pancreas^ may be visualised
by 68Ga-sstr-PET-imaging.
Usually this physiologic pancreatic uptake appears as a
Bfaint^ uptake along the head, body, and tail of the pancreas that
is believed to be a result of binding with high affinity to pancre-
atic islet cells that express various sstr subtypes. Pancreatic poly-
peptide (PP) cells are not distributed equally in the gland; they
are the most abundant cell type in the posterior part of the pan-
creatic headwhereas they are scarce or absent in the remainder of
the gland. This lobe probably originates from the ventral pancre-
atic bud during embryogenesis [10]. Variability in the normal
expression of sstr1-5 subtypes among the different human endo-
crine pancreatic cells was shown by Portela-Gomes et al [11]. Sst
generally exerts inhibitory effects on hormone release produced
in the pancreatic islets [12] mediated through the five known G
protein-coupled sstr subtypes [13].
Sstr binding affinity of 68Ga-sstr-ligands
Different sst-analogues have been introduced for 68Ga-sstr-
PET-imaging over the past 10 years, with the first PET-
imaging studies in humans performed with 68Ga- 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-
Tyr3-octreotide (TOC) [14]. The small structural change
achieved by introducing the metal gallium instead of other
trivalent metals (indium, yttrium, lutetium) appeared to impact
the affinity profile for the different sstr-subtypes (Table 1,
[15–18]). Furthermore, the pharmacokinetic properties also
showed improvement [15]. The Ga-complexes of sst-
analogues commonly show a higher binding affinity for sstr2
when compared with the corresponding complexes with indi-
um, yttrium, or lutetium. The increased hydrophilicity of the
Ga-complex furthermore results in an increased renal elimina-
tion. Together with an improved accumulation of 68Ga-
DOTA-TOC in the tumour lesions these pharmacokinetic
properties lead to a high lesion contrast within a short time
interval post injection, which is of particular importance con-
sidering the short half-life of 68Ga (68 min). Ga-DOTA- Tyr3-
octreotate (TATE) with a C-terminal threonine instead of the
corresponding amino alcohol in DOTA-TOC shows a 10-fold
higher affinity towards sstr2, whereas the affinity to sstr3 and
sstr5 is reduced and the affinity to sstr4 is increased when
compared with Ga-DOTA-TOC. Ga-DOTA- 1-Nal3-
octreotide (NOC) with tyrosine in position 3 replaced for 1-
naphtyl-alanine shows a similar sstr2-binding affinity together
with a more than 10-fold increased affinity for sstr3 and sstr5
in comparison to Ga-DOTA-TOC and a similar affinity to
sstr4 when compared to Ga-DOTA-TATE [16].
Table 1 Affinity profiles of sst
analogues Peptide sstr1 sstr2 sstr3 sstr4 sstr5
DOTATOC >10,000 14± 2.6 880 ± 324 >1,000 393 ± 84
DOTATATE >10,000 1.5 ± 0.4 >1,000 453 ± 176 547 ± 160
DOTALAN >10,000 26± 3.4 771 ± 229 >10,000 73± 12
Ga-DOTATOC >10,000 2.5 ± 0.5 613 ± 140 >1,000 73± 21
Ga-DOTATATE >10,000 0.2 ± 0.04 >1,000 300 ± 140 377 ± 18
Ga-DOTANOC >10,000 1.9 ± 0.4 40.0 ± 5.8 260 ± 74 7.2 ± 1.6
Y-DOTATOC >10,000 11 ± 1.7 389 ± 135 >10,000 114± 29
Y-DOTATATE >10,000 1.6 ± 0.4 >1,000 523 ± 239 187 ± 50
Y-DOTANOC >1,000 3.3 ± 0.2 26 ± 1.9 >1,000 10.4 ± 1.6
Y-DOTALAN >10,000 22.8 ± 4.9 290 ± 105 >10,000 16.3 ± 3.4
The table lists the values for the inhibitory constant (nmol/L) for sstr-binding peptides and their gallium and
yttrium complexes. The IC50-value indicates the concentration when 50 % of binding is inhibited
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Pancreatic sstr-imaging—sensitivity, specificity,
and SUVmax (Table 2)
Sstr-PET is nowadays the established standard method for
molecular imaging of NET. A detailed procedure guideline
for PET/CTwith 68Ga-sst-analogue imaging was summarised
by the Oncology Committee of the EANM [19] This (early)
guideline already mentions that physiological focal tracer up-
take may mimic tumour disease in the pancreas, most fre-
quently in the head/uncinate process, and also strongly recom-
mends anatomical localisation with other imaging modalities.
Here, we overview the currently available data on the di-
agnostic performance of 68Ga-sstr-PET in the detection of
PNETs. We understand that patients at various centres occa-
sionally have undergone surgery for suspected PNETs
visualised by sst analogs in which no tumours were ultimately
identified by pathohistology.
Data for 68Ga-DOTA-TOC-PET
In the first prospective publication [20] in 84 patients with
known or suspected NET we described an increased uptake
in the pancreatic head in 57 (67.8 %)/84 patients, but we did
not quantify the uptake in terms of SUVmax.. The criteria for
visual study interpretation involved a malignant pancreatic
head: an irregular or protrusive shape of finding and clear
delineation from adjacent tissue with higher uptake than the
liver. By these criteria, PET identified 23 findings in the pan-
creas while there were only 21 identified with SPECT and 19
with CT. Only one false positive (FP) finding with an en-
hanced tracer uptake in the pancreatic head was found in a
patient who had clinical symptoms in terms of persistent diar-
rhoea suggestive for a PNET (Fig. 3).
One of the first papers on SUVmax-calculation [21] indicat-
ed that individual sstr-mediated tumour uptake shows a large
range of variation. In this retrospective study the SUVmax-
values for tumours were ranging between 6.4 and 267, but
not all tumours of this study were NETs. The study was aimed
at evaluating if calculation would predict a response to peptide
receptor radionuclide therapy (PRRT). In seven patients, ma-
lignant lesions of the pancreas were used for assessment of
treatment response. These seven patients showed high
SUVmax-values upon the initial visit (mean 43.6; range
20.5–94). Although the reference standard (clinical follow-
up by CT or MRI) indicated progressive disease (PD) in four
patients and stable disease (SD) in three patients, a significant
decline of overall SUVmax-values was observed with regard to
the pancreatic lesion (mean 28.9; range 18–28.9) after
finalisation of PRRT. It is open for discussion as to whether
the decline of tracer uptake despite PD presents a partial ther-
apy success in terms of mixed response or whether it indicates
a further step towards dedifferentiation at a cellular level.
In order to evaluate and establish the 68Ga-DOTA-TOC
uptake for PNET lesions and differentiate the physiologic
pancreatic uptake, our group calculated the SUVmax [22].
The SUVmax amounted to 34.6 ± 17.1 for PNET lesions
(n=43). We differentiated these lesions and calculated 33.6
±14.3 for tumours of the uncinate process (n=30) and 36.3
±21.5 for the pancreatic tail (n=13). The pancreatic body
served as Bnormal pancreas^ for calculating the ratios.
BNormal^ pancreas was defined as faint/no uptake. Finally, a
mean cut-off SUVmax-value of 17.1 was assessed for differen-
tiating tumours in the uncinate process with a specificity of
93.6 % and a sensitivity of 90 %. At this cut-off value we
found true positive (TP) = 27, FP = 20, false negative
(FN)=3, true negative (TN)=290, and the three cases of FN
(i.e., CT-positive) with SUVmax-values of 14.7, 12.8, and 11.7.
We concluded that physiological uptake can pose difficulties
in correctly analysing this region. In our cohort of >1500
68Ga-DOTA-TOC-PET/CT scans (years 2010–2014), 115
studies were performed to detect or exclude pancreatic malig-
nancy (unpublished data): for 14 patients who underwent sub-
sequent surgery, the SUVmax-data of histopathologically ver-
ified PNETs indicated large variation, for the uncinate process
33.2±15.1 (n=3), pancreatic body 57.9±67.6 (n=3), and the
pancreatic tail 47.2±39.7 (n=9). Cut-offs obtained by ROC
(Receiver Operating Characteristic) analyses were 17.1 for the
uncinate process (specificity 92 %; sensitivity 100 %), for the
pancreatic body 14.4 (specificity 100 %; sensitivity 100 %)
and for the pancreatic tail 12.0 (specificity 92.5; sensitivity
88.9 %).
Al-Ibraheem et al. [23]. reported no visual uptake in the
pancreatic head in 20 of 43 (46.6 %) consecutive patients . In
the other 23 patients (53.4 %) either focal uptake (n=10) or an
irregular uptake pattern (n=13) were observed. The SUVmax
for the 20 patients without visual uptake amounted to 4.0±0.8
(range 2.4 to 5.3). For another 20 patients with noticeable
uptake without malignancy (eight patients with focal uptake,
12 patients with irregular uptake) the SUVmax amounted to
9.3±3.1 (range 5.1 to 15.5). In subsequent studies, malignan-
cy could only be histologically proven in three patients (two
with focal and one with irregular uptake) and the SUVmax in
these patients amounted to 51.6±15.7 (range 34.1 to 64.2).
The authors concluded that if the uptake in the pancreatic head
is similar to the uptake in the liver, then a physiological con-
dition is most likely, but also noted that misalignment due to
respiratory motion must always be taken into account.
Kumar et al. [24] found 100 % sensitivity for detecting
primary pancreatic tumours as well as metastatic disease and
reported that the detection rate of PET/CT was higher com-
pared to CT alone, both for primary tumours (20 versus 15) as
well as metastases (13 versus seven). They reported no signif-
icant correlation of SUVmax-values with tumour size. Primary
tumours were localised in the pancreatic head in seven, in the
body in nine and in the tail in three patients. Median SUVmax
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of primary tumours amounted to 12.6 (range 8.8 to 27.6),
similar to the values reported by Prasad and Baum [25] for
68Ga-DOTA-NOC. In Fig. 2 they show a case of significant
uptake in the pancreatic head on PET/CT, which was later
verified by pathohistology to be a well-differentiated NET
lesion (SUVmax 12.6; personal communication). The authors
state that there was no FP for primary PNETs and that all
tumours were seen on 68Ga-DOTA-TOC-PET.
Jacobsson et al. [26] retrospectively analysed their cohort
and reported physiological 68Ga-DOTA-TOC-uptake in the
uncinate process in 35/50 (70 %) patients. These authors cal-
culated a mean SUVmax of 9.2±2.9 for the uncinate process
using an isoactivity cut-off of >75 % and >50 % that equated
to 7.8 and 6.0, respectively. The uncinate process activity ver-
sus pancreas body and tail varied between 3.0 and 4.3.
Data for 68Ga-DOTA-NOC-PET
Prasad and Baum [25] reported an SUVmax-value of 5.8±2.0
(range 4–9.7) for the physiological uptake of the uncinate
process (n=50) and significantly higher SUVmax-values for
PNETs (20.8 ± 10.8; n=26), providing high target to non-
target ratios. The authors suggested that the uncinate process
can be differentiated from pancreatic tumours with high diag-
nostic accuracy at an SUVmax-cut-off of 8.6 (sensitivity 92 %,
specificity 94 %).
Castellucci et al. [27] retrospectively assessed 100 patients
and identified 23 % diffuse and 8 % focally increased pancre-
atic tracer uptake in patients with extra-pancreatic NETs in
whom follow-up PET indicated no change of SUVmax-values
over time, thus suggesting no disease. The SUVmax was 12.6
Fig. 3 Patient with Bfalse positive^ 68Ga-DOTA-TOC uptake. a 68Ga-
DOTA-TOC PET of patient S.J. before surgery in 2004. The images
clearly indicate significant accumulation in the pancreatic head/
uncinate. b 68Ga-DOTA-TOC PET (MIP) of patient S.J. after surgery in
2005, 2008, 2011. The images indicate stable accumulation in the follow-
up period. Despite the significant accumulation in the pancreatic head/
uncinate process, surgical exploration gave a benign histology and further
follow-up studies with either PET or CT did not confirm a malignant
finding. Therefore, this finding was considered a BFP^ PET-result in the
follow-up for the publication in 2007 [20]. The patient had further follow-
up PET/CT scans performed in 2008 and 2011 that were both positive
again for the same location. The SUVmax calculated for the uncinate
process was 26.9 in 2008 and 26.5 in 2011, showing that the SUVmax
remained stable over time, though the tumour markers chromogranin A
(CGA) and neuron specific enolase (NSE) remained elevated in 2011.
This patient is still alive in 12/2015 and in good clinical condition
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±2.2 for those with focal uptake and 5.0±1.6 for diffuse up-
take. The values refer to uptake in the head/uncinate process
without known pathology albeit no histology was obtained.
The authors state that the pancreatic pattern of uptake
remained unchanged, regardless of whether it was focal, dif-
fuse, or absent. They could not confirm the low cut-off value
suggested by the Bad Berka group [20] or come close to our
Innsbruck suggestion that the mean SUVmax-cut-off between
benign and malignant pancreatic tissues should lie somewhat
Bhigher .^
However, in a bi-centric study [28] in 59 NET-patients with
unknown primary PNETs, PET/CT were able to localise the
tumours in 35/59 (59 %) patients, including 16 patients with
PNETs (five head, four body, three tail, three multifocal, and
one uncinate process). Notably, primary PNETs found on CT
after retrospective analyses were reported in 8/16 patients
(50 %)! The mean SUVmax of previously identified unknown
primary PNETs was 18.6±9.8 (range 7.8–34.8) and the mean
SUVmax in patients with a previously known PNET was 26.1
±14.5 (range 8.7–42.4), suggesting that patients with known
primary PNETs have higher sstr expression. Notably, the au-
thors present a case of multifocal PNET in Fig. 2a of their study
that was only detected by PET/CTat the pancreatic tail but was
missed by endoscopic ultrasound (EUS). Furthermore, the av-
erage time interval between the first biopsy-proven diagnoses
of NET and the first evidence of a primary tumour on PET/CT
was found to be approximately 29 months!
Krausz et al. [29] reported for 35 PNETs an SUVmax rang-
ing between 5.5 and 165 (mean 25.7±28.8). Among 63 cases
without previously known pathology, uptake was suspicious
for tumour in 24 cases with an SUVmax ranging between 4.7
and 35 (mean 16.3±8.0). In 38 sites they judged this uptake as
physiological, generally lower relative to adjacent structures
(SUVmax 2.2–12.6; mean: 6.6 ± 2.2). In 24 scans with
suspected tumour and in 37/38 scans with physiological up-
take, diagnostic CT/MRI/EUS failed to detect tumour, sug-
gesting that these investigations do not significantly add to a
diagnosis if uptake is observed in the pancreatic uncinate. No
ROC analysis is available because of low specificity and sen-
sitivity rates.
Sharma et al. [30] reported a mean overall SUVmax for
primary PNETs of 14.7±6 (range 5–32.5), which was signif-
icantly higher than that of metastases overall (P=0.001), as
well as in the diagnosis/staging (P=0.041) and restaging
(P = 0.0003) subgroups. For the staging/diagnosis group
(n=88), the overall sensitivity was 73 %, specificity was
50 %, and accuracy was 70.4 %, and these values were sig-
nificantly lower (p<0.0001) when compared to the restaging
group (98.6, 100, 98.8 %, respectively). Of the 88 studies, 57
were TP, five were TN, five were FP and 21 were FN, and of
the latter ones most of these were known or suspected
insulinomas. In the non-insulinoma group the sensitivity was
100 %, specificity was 57.1 %, and accuracy was 94.8 %.
Data for 68Ga-DOTA-TATE-PET
Poeppel et al. [31] reported in 40 patients (head-to-head com-
parison) with metastasised NETs that significantly fewer le-
sions were detected by 68Ga-DOTA-TATE as compared to
68Ga-DOTA-TOC (p<0.05, 254 vs. 262 lesions), but no over-
all difference was found for detection of regions (78 vs. 79
regions were positive). However, the SUVmax-values were
significantly lower for 68Ga-DOTA-TATE compared to
68Ga-DOTA-TOC (p< 0.01; 16.0 ± 10.08 vs. 20.4 ± 14.7)
across all lesions including those of the pancreas.
In contrast, Kabasakal et al. [32] reported in a head-to-head
comparative study a comparable diagnostic accuracy for both
sstr peptides in 20 tumour patients on a visual scale. However,
68Ga-DOTA-TATE identified 14more tumour lesions because
of superior uptake compared to 68Ga-DOTA-NOC. In fact, the
SUVmax-values calculated for the lesions were significantly
higher, with 29.9±26.4 for 68Ga-DOTA-TATE compared to
24.5±20.3 for 68Ga-DOTA-NOC (p<0.001). Pancreatic up-
take was not further classified in this paper.
A prospective study from London [33] performed in 18
patients reported a lesion-based overall sensitivity of 93.5 %
for 68Ga-DOTA-NOC compared to 85.5 % for 68Ga-DOTA-
TATE, which was due to a significantly (p<0.001) higher
detection of liver metastases. As for PNETs, 68Ga-DOTA-
NOC detected 7/8 whereas 68Ga-DOTA-TATE detected only
3/8 lesions. In two patients with MEN 1 68Ga-DOTA-TATE
detected only one PNETwhereas 68Ga-DOTA-NOC detected
multiple PNETs. Both tracers detected an uncinate process
lesion in two patients that were not confirmed by cross-
sectional and follow-up imaging and were therefore regarded
as FP. The SUVmax-values for the physiological pancreas were
significantly (p< 0.001) higher for 68Ga-DOTA-TATE as
compared to 68Ga-DOTA-NOC (3.5, 3.0–4.3 vs 2.5, 2.0–
3.4). The same group also reviewed their cohort of 728 pa-
tients and found 14 FP scans out of 1258, four of them for the
pancreas, with an overall sensitivity of 97 % and specificity of
95.1 %, and change in treatment management in 41 % of
patients owing mainly to new unexpected findings [34].
In a retrospective evaluation Hofman et al. [35] communi-
cated a high impact on patient management, including cura-
tive surgery, by identifying a primary site and directing pa-
tients with multiple metastases to systemic therapy. Uncinate
process uptake was generally not seen on 111In-octreotide im-
aging but was visualised in 32% (n=19) by PET. One FP case
was due to moderately increased uptake in the uncinate pro-
cess that appeared particularly prominent. This case was con-
cordant with a previous 111In-octreotide scan and was per-
formed to exclude additional disease. The patient underwent
surgery and histology revealed no evidence of a NET, al-
though the referrer marked that the patient’s symptoms and
biochemistry improved. They also demonstrate the case of a
previously unknown PNET in Fig. 4.
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Kunikowska et al. [36] reported increased physiological
uptake in the uncinate process in 41/250 patients (16.4 %)
with an SUVmax of 9.2±3.3. In this study, sites of physiolog-
ical focal uptake were confirmed to be disease-free in subse-
quent follow-up imaging studies as well as in clinical follow-
up. The authors also reported in one patient a 1-cm lesion that
was only detected by DW-MRI, and subsequent surgical re-
section revealed an adenocarcinoma with hyperplasia of neu-
roendocrine cells (Fig. 8 of their paper, SUVmax 7.2; personal
communication).
Haug et al. [37] indicated a sensitivity of 81 % and a speci-
ficity of 90 %, resulting in an accuracy of 87 % with seven FN
and seven other FP cases in suspected NETs. They also reported
a change in surgical management in 9/44 (20 %) of patients;
among those were 6/18 (33 %) patients with PNETs [38].
Schmid-Tannwald et al. [39] showed that 68Ga-DOTA-
TATE-PET/CT is more sensitive than DW-MRI in the detec-
tion of PNETs in 18 patients in the first direct head-to-head
comparative study of patients with histologically proven well-
differentiated or intermediate PNETs. The cohort comprised
five lesions in the head, three in the uncinate process, six in the
body and nine in the tail. In this study, the SUVmax for the
PNETs were 36.46 ± 27.38, range 6.2–120. In Fig. 4 they
show the case of a patient with PNET that could neither be
visualised byDW-MRI nor CT. Only the fused PET/CT image
made the lesion clearly identifiable by its increased uptake of
68Ga-DOTA-TATE.
Similarly, Etchebehere et al. [40] reported for 19 patients a
higher sensitivity of PET/CT over DW-MRI (1.5 T) and
SPECT/CT (99mTc- 6-hydrazinonicotinic acid (HYNIC)-
octreotide). This study was performed prospectively and in-
cluded a biopsy of suggestive lesions. For the pancreas, PET/
CT detected more lesions versus SPECT/CT (P=0.0455) and
WB-DWI (p<0.0455) including a case of unknown primary
in the pancreas uncinate (sensitivity 100 %, specificity 80 %,
accuracy 84 %), but also reported on one FP-uptake in the
process uncinate. Notably, in Fig. 1 the authors demonstrate
the case of an unknown primary which was clearly marked
only on 68Ga-DOTA-TATE-PET/CT while neither SPECT/
CT norMRI identified the tumour. Only retrospective analysis
detected the primary (0.4 cm lesion) on dedicated CT per-
formed 4 years previously!
Data for other sstr-binding radiopharmaceuticals
68Ga-DOTA- lanreotide (LAN) and 64Cu-DOTA-TATE-PET
The only PNET imaged by 68Ga-DOTA-LAN, which was
negative by 68Ga-DOTA-TOC, exhibited an SUVmax of 6.5
[41]. Pfeifer et al. [42] reported a case of previously unknown
PNET that was only confirmed 6 months later on CT in a
patient with MEN I syndrome.
Accuracy of SUVmax-determination and limitation
Sstr targeting is demonstrated by visualisation of tumour
lesions. This visualisation is based on an increased ex-
pression of sstr by tumour lesions [8, 9]. There is a
Bvisual scale^ introduced initially by the group of
Krenning et al. [43], but several other groups have also
tried to quantify the sst tracer uptake. This can be
(semi) quantified by SUVmax or dosimetry calculation
and qualifies a patient as being sstr-positive on a scan
with potential for PRRT [44]. Several factors may inter-
fere with SUVmax-calculation.
Fig. 4 Patient with Btrue positive^ 68Ga-DOTA-TOC uptake. a 68Ga-
DOTA-TOC PET of patient R.R. before surgery in 2005. The images
clearly indicate significant accumulation in the pancreatic body. b 68Ga-
DOTA-TOC PET (MIP) of patient R.R. before and after surgery in 2005
and 2009. The images indicate no tumour recurrence. This female patient
[20] aged 28 years had a 1-cm hypodense lesion on CT as well as an
elevated uron specific enolase (NSE) and chromogranin A (CGA), and
underwent surgery. Histology was a well-differentiated PNET and no
metastases were found in the follow-up PET/CT scans in 2005 and
2009. The SUVmax of the lesion was 15
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Sstr-binding affinity
The discussion was raised that the (slightly) different sstr2-
binding affinities for 68Ga-DOTA-TOC, 68Ga-DOTA-NOC,
and 68Ga-DOTA-TATE may result in a somewhat different
SUVmax for tumours and probably also for the physiologic
uptake. Direct comparative head-to-head PET/CT data were
published only in few numbers of patients [31–33]. Due to the
10-fold higher binding affinity for the sstr2 subtype, DOTA-
TATE may theoretically bear the potential for better tumour
detection. Interestingly, the comparative study of 68Ga-
DOTA-TOC and 68Ga-DOTA-TATE exhibited a higher tu-
mour uptake for 68Ga-DOTA-TOC [31]. The higher affinity
of 68Ga-DOTA-TATE to sstr2 could be contra-balanced by the
higher affinity of 68Ga-DOTA-TOC to sstr5. The two
radioligands showed, however, a high inter- and intra-patient
variability and possessed a comparable diagnostic value for
the detection of NET lesions. Potential advantages of 68Ga-
DOTA-TOC are the superior SUVmax derived for tumour le-
sions and the higher tumour-to-kidney ratio. For 68Ga-DOTA-
NOC a better visualisation of normal organs, especially the
spleen, was reported because of the broader subtype affinity
profile [45]. 68Ga-DOTA-NOC showed a lower normal liver
and pancreas uptake with respect to 68Ga-DOTA-TATE,
allowing for a higher detection rate of liver metastases and
PNETs. On the other hand, 68Ga-DOTA-TATE showed a
higher uptake in organs with predominant sstr2 expression
and in bone metastases than 68Ga-DOTA-NOC. 68Ga-
DOTA-NOC PET was shown to be superior in the detection
of PNETs, however, with both tracers FP results for the pan-
creatic uncinate were reported [33]. Similar FP findings have
been reported for 68Ga-DOTA-TOC and 68Ga-DOTA-NOC
by others [22, 27].
Uptake in normal pancreas is thought to be based on
the presence of sstr on the islet cells [46]. High concen-
tration of sstr2 has been consistently found on pancreatic
α- and β-cells but sstr3 and sstr5 concentration is still
controversial. This normal expression may increase the
risk of FP findings. However, Wittingen and Frey [47]
demonstrated that the islet concentration in the tail is
greater as compared with the uncinate head/body, which
does not support this hypothesis. The controversial ex-
pression of sstr may be one reason for the considerable
overlap of the values reported in the literature, though
physiological uptake in the pancreas was generally asso-
ciated with lower SUVmax-values compared to tumour le-
sions. Furthermore, the calculated SUVmax-values for
PNETs may have a broad range of variation as indicated
in Table 2. Whereas Miederer et al. [48] found a positive
correlation of SUVmax with the sstr2 expression using
68Ga-DOTA-TOC-PET/CT, there is some evidence that
at an SUVmax greater than 25 the calculation may not
reflect solely sstr expression of tumours [49].
Scanner resolution and image reconstruction techniques
The tomographic resolution of a PET scanner and the method
of data reconstruction significantly affect SUVmax-calculation,
especially for small NET lesions with high uptake. In a com-
parison of standardised protocols with 23 dedicated PETscan-
ners Geworski et al. [50] demonstrated errors of up to 10 % in
SUVmax-values. Furthermore, many centres were not able to
maintain accurate SUVmax-calibrations without additional su-
pervision, which can be another hindrance of reasonable
SUVmax-calculation [51].
Time of flight (TOF) is a valuable method for acquiring the
signal-to-noise ratio [52]. Basically, TOF generates an in-
crease in SUVmax. Therefore, the use of TOF has to be taken
into account when comparing SUV values.
In recent years new reconstruction algorithms have contin-
uously been developed that mainly confirm under the notation
Bresolution recovery .^ These improving algorithms take
known scanner, bed, and physical geometries into account
and vary from vendor to vendor. On the one hand they may
enhance the signal-to-contrast ratios, and on the other hand,
theymay also reduce the activity administered to the patient or
reduce the time per bed position. The common hurdles to
introducing these patient exposure-reducing and image-
improving algorithms quickly into daily routine are the signif-
icant costs, the need for physician training and familiarity with
modified images, and the strongly reduced possibility to use
the different reconstructed images for follow-up comparison.
Therefore, the PET scanner scene is very heterogenic in terms
of technological standard (e.g., TOF or nonTOF) and the use
of modern reconstruction algorithms. This makes it almost
unreliable in comparison of SUVmax-values from sites with
different scanners.
The Innsbruck data with 68Ga-DOTA-TOC [22] were de-
rived with the use of TOF and geometric modelling (VuePoint
FX, GE®), contrary to the reconstruction methods used in the
studies reported by Prasad and Baum [25] with 68Ga-DOTA-
NOC and Poeppel et al. [31] with 68Ga-DOTA-TATE.
Other factors
Tracer uptake time
The initial patient study [20] clearly demonstrated that serial
acquisition at different time points (20, 60, and 100 min p.i.)
provide different results with regard to image quality and
count ratios. Based on the pharmacokinetics on one hand
and on the rapid isotope decay on the other, the optimal time
point for scanning should be 100 min p.i.. However, time
points for scanning are still not standardized [43], but would
be an important methodological requirement for comparison
of semi-quantitative parameters.
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Peptide mass
Some evidence suggests that the peptide mass may potentially
influence the in-vivo binding and subsequently SUVmax [53],
but there exist no further data on this hypothesis.
Motion
Difficulties in image interpretation may also stem from respi-
ratory motion contributing to FP pancreatic uptake. Therefore,
attenuation correction is essential [54].
Influence of PRRT and other therapies
Receptor downregulation may become a problem under dif-
ferent therapy modalities and may also change receptor den-
sity due to dedifferentiation in the course of disease [45].
Impact for patient management
PNETs can present with various symptoms and clinical out-
comes. Symptomatic tumours include insulinomas,
gastrinomas, glucagonomas, VIPomas, and somatostatinomas,
but most of the PNETs are non-functioning and present fairly
late, usually with liver metastases. Thus, early and accurate
localisation of primary tumours and metastases is essential for
further patient management.
Hyperplastic changes of the NET cell may have the poten-
tial to evolve into neoplastic disease. This is particularly the
case in the setting of MEN syndromes. Pseudohyperplasia of
islet cells of the pancreatic head, however, is believed to be an
age-dependent condition that differs from hyperplastic neo-
plastic NET disease [55]. The pancreas of patients with
MEN1 (Fig. 2) typically contains multiple small NET-
microadenomas [56]. It is supposed that the allelic loss of
11q13 in an islet cell sets the stage of NET development [57].
To our knowledge, no prospective study has so far specif-
ically addressed the diagnostic performance with regard to the
pancreas. The only information about the diagnostic perfor-
mance of PET/CT has been derived from several retrospective
studies using different sstr-avid tracers and protocols present-
ed herein. Therefore, a standardised protocol is not yet avail-
able that especially addresses the knowledge about specificity
of the technique. Are BFP findings^ real non-tumour foci in
PET/CT?What is the gold standard in this situation? Surgery?
Follow-up? The uncertainty of this issue may also result in a
patient tragedy [58].
Besides visual criteria to define abnormalities, the most
attractive way to differentiate normal and abnormal pancreatic
uptake might be based on quantitative parameters, in particu-
lar SUVmax-values. However, the retrospective analyses show
some discrepancies with regard to this parameter. For
instance, we [22] found an SUVmax of 17.1 for
68Ga-DOTA-
TOC that was best suited to discriminate between malignant
and non-malignant lesions irrespective of the lesion diameter
using ROC curves, while several other groups proposed some-
what different cut-off values. Extrapolating the data from the
studies, the SUVmax cut-off for
68Ga-DOTA-TATE should be
around 20 and for 68Ga-DOTA-NOC more than 20 [31–33].
While we initially could not demonstrate a relevant clinical
value of SUVmax changes derived from
68Ga-DOTA-TOC
studies in patients treated by PRRT [21], in a more recent
publication Ambrosini et al. [59] recently demonstrated for
68Ga-DOTA-NOC that SUVmax is a relevant prognostic factor
in G1- and G2-PNETs. In their retrospective analysis they
showed for 43 patients that at the 24-month follow-up the
SUVmax was significantly (P=0.003) higher for patients with
SD than for those with PD, reporting an SUVmax cut-off of 38.
However, some anecdotal examples show that even high
SUVmax values can be found during repeated investigations
without clinical evidence of tumour development, such as
those shown here in Fig. 3. Therefore, cut-off values should
be cautiously considered in the decision to perform surgery or
not, and to specifically guide the patient management.
Summing up all available data, 68Ga-sstr-PET/CT im-
aging is feasible to rule out well-differentiated PNET in
most cases with high reliability, which can be helpful in
patients where the primary NET site is supposed in the
pancreas. On the other hand, some papers report on the
potential value of SUVmax calculation to assess NET tis-
sue, however, this approach suffers from limitations most-
ly related to technical/methological shortcomings and
sometimes the slow evolution of well-differentiated
NETs. Therefore, prospective studies are required to stan-
dardise the procedure. Despite the frequent finding of en-
hanced uptake in the pancreatic head/uncinate process one
should be cautious to assume this finding as normal to
neglect the origin over time. In this situation at least an-
other cross-sectional imaging modality, preferably DW-
MRI, should be conducted to rule out any irregularity of
the organ. Finally, it was already demonstrated that it is
still possible that with a longer follow-up period some of
the suggested foci that were Bsuspected tumours^ and
could not be verified by CT/MRI/EUS may be found to
contain tumours in the future, such as recently demon-
strated by Prasad et al. [28] or Etchebehere et al [40].
Conclusion
On the basis of the present data, the diagnostic algorithm is to
perform a 68Ga-sstr-PET/CT study on initial staging of the
NET patient since it is superior to sstr-SPECT/CT as well as
to DW-MRI. With regard to the pancreas, however, the defin-
itive accuracy has yet to be defined. A huge scale of results
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can be observed to discriminate tumour from non-tumour
findings by visual and in particular by quantitative scoring,
from which it is not possible to make definite recommenda-
tions. The major limitation in most of these (single-centre)
studies lies in the lack of histopathological confirmation of
abnormal findings and the retrospective design. It must be
mentioned that it is usually not feasible to obtain histopatho-
logical verification due to ethical and practical reasons, and
therefore most of the published studies employed a combina-
tion of clinical and/or imaging follow-up.
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